Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF inact mut |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03989115 | Phase Ib/II | Cobimetinib + RMC-4630 Osimertinib + RMC-4630 | Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC | Completed | USA | 1 |
NCT03634982 | Phase I | RMC-4630 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Unknown status | USA | 0 |
NCT01514864 | Phase II | Dasatinib | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Terminated | USA | POL | GBR | DEU | CAN | BRA | 1 |